Case Report
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 6, 2019; 7(9): 1087-1092
Published online May 6, 2019. doi: 10.12998/wjcc.v7.i9.1087
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report
Xue-Bing Shi, Ji-Fa Jiang, Feng-Xiang Jin, Wei Cheng
Xue-Bing Shi, Ji-Fa Jiang, Feng-Xiang Jin, Wei Cheng, Department of Hematology and Oncology, Tongling People’s Hospital, Tongling 244000, Anhui Province, China
Author contributions: Shi XB participated in patient treatment, collection and analysis of the clinical data and writing of the manuscript; Jiang JF participated in patient treatment, data analysis and manuscript revision; Jin FX helped guide the treatment of the patient and research design; Cheng W took part in the patient’s therapy; All authors read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from both the patient and her spouse for publication of this case report.
Conflict-of-interest statement: The authors declare that they have no conflicts of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xue-Bing Shi, MD, Attending Doctor, Department of Hematology and Oncology, Tongling People's Hospital, Bijiashan Road 468, Tongguan District, Tongling 244000, Anhui Province, China. sxbtlph@163.com
Telephone: +86-562-5838144 Fax: +86-562-5838144
Received: January 25, 2019
Peer-review started: January 25, 2019
First decision: March 14, 2019
Revised: March 21, 2019
Accepted: March 26, 2019
Article in press: March 26, 2019
Published online: May 6, 2019
Core Tip

Core tip: The Janus kinase 2 (JAK2) V617F mutation is rare in breakpoint cluster region-Abelson1 (BCR-ABL1)-positive chronic myeloid leukemia (CML). We report a female CML patient with a JAK2 V617F mutation. This rare subset of CML patients often have notable thrombocythemia in addition to more typical CML features. The patient achieved complete hematological response following 2 mo imatinib treatment. After 3 mo of imatinib treatment, the value of BCR-ABL1 (IS) was 0.143%, but the JAK2 V617F mutation rate rose from 10% to 15%.